In quest for vaccine, US makes 'big bet' on company with unproven technology
Key Excerpts from Article on Website of MSN News
Posted: July 26th, 2020
One by one, vaccine developers at a White House roundtable convened by President Donald Trump in early March pitched their product as a viable solution to the coronavirus. Stéphane Bancel of Moderna Inc. glanced across the table at the nation's top infectious disease expert, Dr. Anthony Fauci, and said he is "very proud to be working with the US government and to have already sent, in only 42 days from the sequence of the virus, our vaccine to Dr. Fauci's team at the NIH." Bancel went on to say that he needed just "a few months" to start phase two of a three-part clinical trial of the sort that typifies vaccine development. (The entire process often takes more than a decade.) The day after the roundtable, the FDA green-lit Moderna's product for trial, making it the first vaccine candidate to advance to the first phase of a clinical study, in which an as-yet unapproved vaccine is injected into the arms of a small group of 45 human volunteers. The effort received another boost on April 16, when the federal Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna up to $483 million to accelerate the development and manufacturing of the vaccine. The FDA allowed Moderna's RNA vaccine ... to essentially gloss over the animal-testing that typically precede clinical trials in humans. [Moderna's former director of chemistry Dr. Suhaib] Siddiqi said this is cause for alarm. "I would not let that [vaccine] be injected in my body," he said. "I would demand: Where is the toxicity data from the lab?"
Note: Read a New York Times/MSN article titled "Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.